These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15298364)

  • 1. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs.
    Phillips KA; Veenstra DL; Ramsey SD; Van Bebber SL; Sakowski J
    Am J Manag Care; 2004 Jul; 10(7 Pt 1):425-32. PubMed ID: 15298364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current impact of gene technology on healthcare. A map of economic assessments.
    Rogowski W
    Health Policy; 2007 Feb; 80(2):340-57. PubMed ID: 16678930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomics and proteomics: the next generation of health care.
    Sica JM
    Empl Benefits J; 2002 Dec; 27(4):18-21. PubMed ID: 12500585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing patient readiness for the clinical adoption of personalized medicine.
    Issa AM; Tufail W; Hutchinson J; Tenorio J; Baliga MP
    Public Health Genomics; 2009; 12(3):163-9. PubMed ID: 19204419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Women's interest in gene expression analysis for breast cancer recurrence risk.
    O'Neill SC; Brewer NT; Lillie SE; Morrill EF; Dees EC; Carey LA; Rimer BK
    J Clin Oncol; 2007 Oct; 25(29):4628-34. PubMed ID: 17925559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular medicine: how, what, and when?
    Woodcock J
    Clin Pharmacol Ther; 2007 Oct; 82(4):376-8. PubMed ID: 17851578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Point-of-care testing: an introduction.
    Gutierres SL; Welty TE
    Ann Pharmacother; 2004 Jan; 38(1):119-25. PubMed ID: 14742805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical, social and legal implications of pharmacogenomics: a critical review.
    Moldrup C
    Community Genet; 2001; 4(4):204-14. PubMed ID: 12751484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Legal issues associated with genetics.
    Carson WY
    Nurs Clin North Am; 2000 Sep; 35(3):719-29. PubMed ID: 10957686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer screening for Korean women must consider traditional risks as well as two genetic risk factors: genetic polymorphisms and inheritable gene mutations.
    Anderson G; Jun M; Choi K
    Cancer Nurs; 2007; 30(3):213-22. PubMed ID: 17510585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychological impact of genetic testing for cancer susceptibility: an update of the literature.
    Meiser B
    Psychooncology; 2005 Dec; 14(12):1060-74. PubMed ID: 15937976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic testing for hereditary cancers: the impact of gender on interest, uptake and ethical considerations.
    d'Agincourt-Canning L; Baird P
    Crit Rev Oncol Hematol; 2006 May; 58(2):114-23. PubMed ID: 16600617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing controversial direct-to-consumer advertising for hereditary breast cancer testing: reactions from women and their physicians in a managed care organization.
    Mouchawar J; Laurion S; Ritzwoller DP; Ellis J; Kulchak-Rahm A; Hensley-Alford S
    Am J Manag Care; 2005 Oct; 11(10):601-8. PubMed ID: 16232001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges.
    Deverka PA; Doksum T; Carlson RJ
    Clin Pharmacol Ther; 2007 Oct; 82(4):427-34. PubMed ID: 17687271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commercialization of genetic testing services: the FDA, market forces, and biological tarot cards.
    Malinowski MJ; Blatt RJ
    Tulane Law Rev; 1997 Mar; 71(4):1211-312. PubMed ID: 15744901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interest, awareness, and perceptions of genetic testing among Hispanic family members of breast cancer survivors.
    Ramirez AG; Aparicio-Ting FE; de Majors SS; Miller AR
    Ethn Dis; 2006; 16(2):398-403. PubMed ID: 17682241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready?
    Shields AE; Lerman C
    Clin Pharmacol Ther; 2008 Apr; 83(4):635-9. PubMed ID: 18323859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic opportunities and challenges for pharmacogenomics.
    Deverka PA; Vernon J; McLeod HL
    Annu Rev Pharmacol Toxicol; 2010; 50():423-37. PubMed ID: 20055709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.